相关实验视频

Updated: Jun 2, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

通过高血压的急性缺血性中风后的早期与延迟的抗高血压治疗病史

Xuewei Xie^1,2, Chongke Zhong³, Xin Liu^1,2

¹Department of Neurology (X.X., X.L., Y.P., Yufei Wei, Y.J., M.W., J.J., X.M., Yilong Wang, Yongjun Wang, L.L.), Beijing Tiantan Hospital, Capital Medical University, China.

|January 14, 2025

概括

在急性缺血性中风中,早期的抗高血压治疗没有改善结果. 它恶化了没有高血压史的患者的功能结果,强调了在中风治疗时间考虑高血压状态的重要性.

科学领域:

神经学神经学
心脏病学心脏病学
临床试验临床试验

背景情况:

在急性缺血性中风II (CATIS-2) 中中国抗高血压试验的子组分析.
在急性缺血性中风患者中研究了早期与延迟的抗高血压治疗效果.
根据先前的高血压史,比较结果.

研究的目的:

为了比较立即与延迟抗高血压治疗的疗效.
评估治疗对急性缺血性中风患者死亡和残疾的影响.
为了确定高血压史是否会改变治疗结果.

主要方法:

在中国进行多中心随机临床试验 (CATIS-2).
4810名患有急性缺血性中风 (静脉血压140-220毫米) 的患者随机.
主要结局:90天后死亡或功能依赖 (mRS ≥3).

主要成果:

无论有过高血压史,早期治疗组和延迟治疗组之间死亡或依赖性没有显著差异.
在没有高血压的患者中,早期治疗显示mRS得分更高的几率 (OR,1.35;95% CI,1.01-1.82).
患有高血压史的患者的mRS得分没有显著差异 (OR,0.95;95% CI,0.82-1.10),具有显著的相互作用 (P=0.04).

结论:

根据高血压史,早期抗高血压治疗没有减少90天内缺血性中风患者的死亡或依赖.
在没有高血压病史的患者中,早期治疗恶化了功能结果.
高血压状态是急性缺血性中风后定时抗高血压治疗的一个关键因素.

关键词:

血压血压血压血压死亡死亡死亡死亡死亡死亡这种高血压,高血压.缺血性中风中风一次性中风中风中风中风中风

更多相关视频

Prehospital Thrombolysis: A Manual from Berlin

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

相关概念视频

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...